ライフサイエンスコーパス: respiratory tract disease

1 m that is commonly associated with localized respiratory tract disease.

2 ion in human infants at risk of severe lower respiratory tract disease.

3 eir activity in preclinical rodent models of respiratory tract disease.

4 ng invasive mechanical ventilation for lower respiratory tract disease.

5 immunogenic and prevented RSV-mediated lower respiratory tract disease.

6 s for the prevention of RSV-associated lower respiratory tract disease.

7 ct symptoms to severe life-threatening lower respiratory tract disease.

8 nd point was hospitalization for RSV-related respiratory tract disease.

9 en with acute respiratory failure from lower respiratory tract disease.

10 y explain why MERS is characterized by lower respiratory tract disease.

11 ory tract and is a common cause of localized respiratory tract disease.

12 primary etiological agent of childhood lower respiratory tract disease.

13 y pathogen that causes acute upper and lower respiratory tract disease.

14 in respiratory specimens of individuals with respiratory tract disease.

15 g the severity of influenza-associated lower respiratory tract disease.

16 icant advances in the investigation of human respiratory tract disease.

17 responsible for a substantial proportion of respiratory tract disease.

18 the respiratory secretions of children with respiratory tract disease.

19 yxovirus that is an important cause of acute respiratory tract disease.

20 tem diseases, gastrointestinal diseases, and respiratory tract diseases.

21 l complex associations with asthma and other respiratory tract diseases.

22 respiratory viruses (RVs) in suspected lower respiratory tract disease, 72 paired NP and bronchoalveo

23 AMRs 27.6), cancer (17.3), and chronic lower respiratory tract diseases (8.3), followed by unintentio

24 st the two leading viral agents of pediatric respiratory tract disease, a bivalent vaccine whose atte

25 vere medically assessed RSV-associated lower respiratory tract disease among infants were lower with

26 s (RSV) is an important cause of acute lower respiratory tract disease among the elderly, but nationa

27 en with acute respiratory failure from lower respiratory tract disease, an extubation readiness test,

28 cluded hospitalization for RSV-related lower respiratory tract disease and hospitalization for respir

29 s (RSV) is the leading cause of infant lower respiratory tract disease and hospitalization worldwide.

30 lus influenzae is a major cause of localized respiratory tract disease and initiates infection by col

31 uenzae (NTHi) is a common cause of localized respiratory tract disease and initiates infection by col

32 Haemophilus influenzae is a common cause of respiratory tract disease and initiates infection by col

33 V antigens are believed to cause exaggerated respiratory tract disease and may also contribute to unw

34 l virus (RSV) is a top cause of severe lower respiratory tract disease and mortality in infants and t

35 to a lower incidence of RSV-associated lower respiratory tract disease and of RSV-associated acute re

36 ases (lung cancer, stroke, and chronic lower respiratory tract diseases) and examined the simultaneou

37 URTI recovered without progression to lower respiratory tract disease, and 10 (83%) of the 12 patien

38 incidence of hospitalization for RSV-related respiratory tract disease as compared with no vaccine.

39 Bordetella avium causes an upper respiratory tract disease (bordetellosis) in avian speci

40 s (RSV) infection causes a substantial lower-respiratory-tract disease burden in infants, constitutin

41 Bordetella avium causes an upper-respiratory-tract disease called bordetellosis in birds.

42 Lower respiratory tract disease can manifest itself as airflow

43 ld be used prophylactically to prevent lower respiratory tract disease caused by hMPV.

44 tes to protect infants from the severe lower respiratory tract disease caused by HPIV3.

45 Lower respiratory tract disease caused by respiratory syncytia

46 cines, antivirals, and other drugs acting on respiratory tract disease caused by RSV.

47 ll cocultures using Moraxella catarrhalis, a respiratory tract disease-causing bacterium, as a biolog

48 S coronavirus (SARS-CoV) causes severe acute respiratory tract disease characterized by diffuse alveo

49 utcomes, including from RSV-associated lower respiratory tract disease, compared to patients without

50 coronaviruses commonly associated with upper respiratory tract disease - coronaviruses 229E, OC43, NL

51 is an important etiologic agent of pediatric respiratory tract disease, could be enhanced by expressi

52 cytial virus (RSV) is a major cause of lower respiratory tract disease, especially in young children

53 .001), while hospitalization rates for lower respiratory tract diseases excluding bronchiolitis did n

54 occal carriage did not impact rates of lower respiratory tract disease for these 3 viruses.

55 >20%), as well as fewer hospitalizations for respiratory tract disease from any cause (284 vs. 335; v

56 ratory tract disease and hospitalization for respiratory tract disease from any cause.

57 he anticipated cases of RSV-associated lower respiratory tract disease had occurred.

58 responsible for a substantial proportion of respiratory tract diseases have not been identified.

59 come was respiratory syncytial virus-related respiratory tract disease hospitalization.

60 respiratory tract and then progress to lower respiratory tract disease in a subset of patients.

61 is the most important cause of severe lower-respiratory tract disease in calves and young children,

62 ) NL63, associated with both upper and lower respiratory tract disease in children and adults worldwi

63 ) are positive-strand RNA viruses that cause respiratory tract disease in children and adults.

64 gen, is associated with both upper and lower respiratory tract disease in children and adults.

65 metapneumovirus (hMPV) is a leading cause of respiratory tract disease in children and is associated

66 (RSV) is a significant cause of severe lower respiratory tract disease in children and older adults,

67 e is a major cause of otitis media and other respiratory tract disease in children.

68 is an important pathogen causing acute lower respiratory tract disease in children.

69 al virus (RSV) is the leading cause of lower respiratory tract disease in children.

70 e during 2023 were efficacious against lower respiratory tract disease in clinical trials.

71 identified as a significant cause of serious respiratory tract disease in humans.

72 roved for prevention of RSV-associated lower respiratory tract disease in individuals >=60 years.

73 ) is an important viral agent causing severe respiratory tract disease in infants and children as wel

74 us (RSV) is the leading viral cause of lower respiratory tract disease in infants and children worldw

75 is the most significant viral cause of lower respiratory tract disease in infants and children.

76 irus, is a major viral cause of severe lower respiratory tract disease in infants and children.

77 s (RSV) is the most important cause of lower respiratory tract disease in infants and children.

78 irus (hRSV) is responsible for serious lower respiratory tract disease in infants and in older adults

79 rus (RSV) is a leading cause of severe lower respiratory tract disease in infants and older adults.

80 virus (RSV) is a major cause of severe lower respiratory tract disease in infants and the elderly, bu

81 lthough a prominent cause of upper and lower respiratory tract disease in infants and the elderly, cl

82 irus (HRSV) is a major cause of severe lower respiratory tract disease in infants and the elderly, ye

83 virus (RSV) infection, a severe acute lower respiratory tract disease in infants and young children

84 al virus (RSV) is the leading cause of lower respiratory tract disease in infants and young children

85 st and second leading viral agents of severe respiratory tract disease in infants and young children

86 al virus (RSV) is the leading cause of lower respiratory tract disease in infants and young children

87 respiratory virus that causes serious lower respiratory tract disease in infants and young children

88 rus type 1 (HPIV1) is a significant cause of respiratory tract disease in infants and young children

89 and is associated with both upper and lower respiratory tract disease in infants and young children.

90 ause of morbidity and life-threatening lower respiratory tract disease in infants and young children.

91 and, if so, whether they are associated with respiratory tract disease in infants and young children.

92 may account for a significant proportion of respiratory tract disease in infants and young children.

93 vere medically assessed RSV-associated lower respiratory tract disease in infants from birth to 6 mon

94 ry etiologic agent of serious epidemic lower respiratory tract disease in infants, immunosuppressed p

95 cytial virus (RSV), the major cause of lower respiratory tract disease in infants, is thought to infe

96 (RSV) is the primary cause of serious lower respiratory tract disease in infants, young children, th

97 is the most important viral cause of severe respiratory tract disease in infants.

98 es to a herpesvirus associated with an upper respiratory tract disease in Mediterranean tortoises [sp

99 yncytial virus (RSV) can cause serious lower respiratory tract disease in older adults, but no licens

100 a major cause of morbidity and severe lower respiratory tract disease in the elderly and very young,

101 a in immunocompetent children and with lower respiratory tract disease in the immunocompromised host.

102 ovine RSV (BRSV) is a primary cause of lower respiratory tract disease in young cattle.

103 tial virus (RSV) is a leading cause of lower respiratory tract disease in young children and elderly

104 irus, is a major etiological agent for lower respiratory tract disease in young children that can man

105 cause of otitis media in children and lower respiratory tract diseases in adults.

106 virus type 3 (HPIV3), a major cause of lower respiratory tract diseases in infants, and the emerging

107 ficacious in preventing RSV-associated lower respiratory tract diseases in older adults.

108 ed for a small but significant proportion of respiratory-tract disease in infants and children.

109 nd resistance to treatment of multiple human respiratory tract diseases including otitis media, chron

110 The prevalence of aspirin-exacerbated respiratory tract disease is approximately 10% and for a

111 ) is the agent of a major global outbreak of respiratory tract disease known as Coronavirus Disease 2

112 estations, including chronic upper and lower respiratory tract disease, laterality defects, and subfe

113 rder, cardiovascular diseases, chronic lower respiratory tract diseases, liver cirrhosis, and spinal

114 Respiratory syncytial virus (RSV) lower respiratory tract disease (LRD) is a life-threatening co

115 yses, more patients with 2009 H1N1 had lower respiratory tract disease (LRD), hypoxemia, and prolonge

116 a increased the risk of progression to lower respiratory tract disease (LRD), hypoxemia, respiratory

117 d virus (75%) had a medically attended lower respiratory tract disease (LRD).

118 ted high vaccine efficacy (VE) against lower respiratory tract disease (LRTD) but enrolled a smaller

119 A multivariate risk factor analysis of lower-respiratory tract disease (LRTD) identified 2 conditions

120 e epidemiology, risk of progression to lower respiratory tract disease (LRTD), and conditions linked

121 er respiratory tract disease (URTD) or lower respiratory tract disease (LRTD), with 60% and 40% of ca

122 ) from immunocompromised subjects with lower respiratory tract disease (LRTD).

123 s at increased risk for RSV-associated lower respiratory tract disease (LRTD).

124 nsplantation (HCT), frequently causing lower respiratory tract disease (LRTD).

125 dies have transformed understanding of lower respiratory tract diseases (LRTDs), including coronaviru

126 vere medically assessed RSV-associated lower respiratory tract disease (MA-RSV-LRTD) in infants until

127 RSV-mediated lower respiratory tract disease meeting case definitions 1, 2,

128 emophilus influenzae, a major cause of lower respiratory tract diseases, must cope with a range of el

129 The lower respiratory tract disease observed in this monkey model

130 g follow-up, hospitalization for RSV-related respiratory tract disease occurred in 3 of 65,642 partic

131 Respiratory tract disease occurs when NTHi adhere to or

132 ognized as a causative agent in this complex respiratory tract disease of cattle.

133 rus (RSV) is a leading cause of severe lower respiratory tract disease of children, the elderly, and

134 e acute respiratory syndrome (SARS), a lower respiratory tract disease of humans that was first repor

135 s frequently observed in patients with upper respiratory tract disease only and more frequently in pa

136 stic techniques and is associated with lower respiratory tract disease, particularly in children.

137 may be the etiological agent responsible for respiratory tract disease, particularly in young childre

138 ich are associated with both upper and lower respiratory tract disease, particularly in young childre

139 acute otitis media, and 8 episodes of lower respiratory tract disease per 1000 children yearly.

140 Viral respiratory tract diseases pose serious public health pr

141 (Abrysvo; Pfizer) prevents RSV-related lower respiratory tract disease-related emergency department (

142 ially isolated from a young child with lower respiratory tract disease, represents a group of newly d

143 A) was efficacious against RSV-related lower respiratory tract disease (RSV-LRTD) in >=60-years-olds

144 A) was efficacious against RSV-related lower respiratory tract disease (RSV-LRTD), severe RSV-LRTD, a

145 ion on the contribution of HMPV to pediatric respiratory tract disease suggests that it will be impor

146 s with AERD have more severe upper and lower respiratory tract disease than do aspirin-tolerant patie

147 fewer hospitalizations for RSV-related lower respiratory tract disease than the control group (1 vs.

148 s the first occurrence of RSV-mediated lower respiratory tract disease that met one of three case def

149 able Haemophilus influenzae (NTHI) can cause respiratory tract diseases that include otitis media, si

150 ses, including strains that cause mild upper respiratory tract disease, their role in historic and fu

151 des were recorded, 791 (74%) with only upper respiratory tract disease (URTD) and 279 (15%) progressi

152 Upper respiratory tract disease (URTD) has been observed in a

153 The infections were categorized as upper respiratory tract disease (URTD) or lower respiratory tr

154 any medically assessed RSV-associated lower respiratory tract disease (vaccine efficacy, 65.5%; 95%

155 vere medically assessed RSV-associated lower respiratory tract disease (vaccine efficacy, 69.0%; 95%

156 in nasopharyngeal colonization and localized respiratory tract disease, we assessed their expression

157 old listing bronchiolitis, pneumonia, or any respiratory tract disease were examined.

158 Rates of acute otitis media and lower respiratory tract disease were highest among children ag

159 nfluenzae is an important cause of localized respiratory tract disease, which begins with colonizatio

160 tial virus (RSV) is a leading cause of lower respiratory tract disease, which causes high rates of mo

161 otal trial's efficacy endpoints of RSV lower respiratory tract disease with >=2 or >=3 signs/symptoms

162 were the prevention of RSV-associated lower respiratory tract disease with at least two signs or sym

163 , 66.0 to 92.2) against RSV-associated lower respiratory tract disease with at least two signs or sym

164 us (HRV) is a major cause of upper and lower respiratory tract disease worldwide and displays conside

165 st important viral agent of severe pediatric respiratory tract disease worldwide, but it lacks a lice

166 ncytial virus (RSV) is an important cause of respiratory tract disease worldwide, especially in the p

167 fied in 2001, is a causative agent of severe respiratory tract disease worldwide.

168 nfluenza A virus (IAV) is a leading cause of respiratory tract disease worldwide.

169 he most important agent of serious pediatric respiratory tract disease worldwide.

170 ond most important viral agents of pediatric respiratory tract disease worldwide.

171 t important viral agent of serious pediatric respiratory-tract disease worldwide.